Data regarding systemic therapies in the management of atopic dermatitis are limited. The aim of this study was to provide evidence for the efficacy and tolerance of systemic immunosuppressive treatments for moderate-to-severe adult atopic dermatitis. A single-centre retrospective study was conducted. A total of 54 patients were prescribed systemic treatments between 2000 and 2014. Of these, 28 received methotrexate and 55.6% were considered as responders based on Physician's Global Assessment, 17 received azathioprine (37.5% responders), 43 received cyclosporin A (65.9% responders) and 7 received a combination therapy with methotrexate and azathioprine (57.1% responders). These treatments were well-tolerated overall and few adverse events required discontinuation of treatment. Combination therapy associating methotrexate and azathioprine appears to be a promising treatment for patients who fail to respond to conventional monotherapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-2389 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Does atopic dermatitis increase the risk of allergic contact dermatitis?
Immunol Lett
January 2025
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address:
Laboratory changes during dupilumab treatment for atopic dermatitis.
Actas Dermosifiliogr
January 2025
Dermatology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.
The Objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.
Investigating the efficacy of gliclazide encapsulated hydrogel in the preclinical mice model for atopic dermatitis.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow, UP, Lucknow, 226002, India.
Atopic dermatitis (AD) is a chronic skin inflammatory ailment commonly observed in young children and adults. Various therapeutic modalities are already explored for mitigation of AD but for prolong application very few modalities are recommended. Considering these challenges, we have successfully developed gliclazide-loaded hydrogels using the physical dispersion method.
View Article and Find Full Text PDFDiverse Colonisation and Disease Associations of the Human Commensal Malassezia: Our Body's Secret Tenant.
Mycoses
January 2025
Cell Biology and Molecular Genetics, Yenepoya Research Centre, Yenepoya (Deemed to Be University), Mangalore, India.
A niche in the context of microorganisms defines the specific ecological role or habitat inhabited by microbial species within an ecosystem. For the human commensal Malassezia, the skin surface is considered its primary niche, where it adapts to the skin environment by utilising lipids as its main carbon and energy source. However pathogenic characteristics of Malassezia include the production of allergens, immune modulation and excessive lipid utilisation, which result in several diseases such as pityriasis versicolor, seborrheic dermatitis, Malassezia folliculitis and atopic dermatitis.
View Article and Find Full Text PDF[Consensus for the treatment of atopic dermatitis in primary care: resolving myths and legends based on evidence].
Rev Alerg Mex
December 2024
Universidad Espíritu Santo, Samborondón, Guayas, Ecuador.
Article Synopsis
- Atopic dermatitis (AD) greatly affects patients' quality of life, and existing guidelines often target specialists instead of primary care physicians (PCPs).
- A study aimed to create a consensus document specifically for PCPs, offering evidence-based recommendations to enhance AD patient diagnosis and management.
- The document identifies obstacles PCPs face in implementing guidelines and provides consensus solutions to improve care for AD patients across different medical specialties.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!